Drug intelligence / Profile preview

EVD-001

Development stage: Preclinical
Lead developer: Evozyne
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

EVD-001 is an engineered IgG protease being developed by Evozyne for the treatment of rare autoimmune diseases. It is designed to selectively degrade pathogenic immunoglobulin G (IgG) while preserving broader immune function. Unlike first-generation IgG proteases, EVD-001 is engineered for subclass selectivity and reduced immunogenicity, which may allow for redosing in chronic conditions. The program is currently in the IND-enabling phase, with an initial Investigational New Drug (IND) submission targeted for 2026.

Targets

IgG (Immunoglobulin G)

Beyond the preview

Go deeper on EVD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVD-001.

Explore the full profile